Dow & Colorcon extend scope of Controlled Release Alliance
Colorcon Inc. and The Dow Chemical Company announced
an agreement to broaden the existing Controlled Release Alliance between the
two companies. While the Alliance currently provide controlled release
technologies from Dow Pharma & Food Solutions, a business unit of Dow, to
customers, effective January 1, 2017, it will be extended to include Dow’s advanced technology based
pharmaceutical excipients.
The Alliance has served the needs of the
pharmaceutical industry, since announced in July 2007, providing customized
solutions, products and support services for pharmaceutical product
development. The addition of new technologies into the Alliance product
portfolio expands the existing relationship between Colorcon and Dow and
further enables formulation and development of fast-growing pharmaceutical
applications, beyond the existing controlled release scope.
“This
new phase reaffirms the long-standing commitment between the two companies to
grow together and leverage their respective strengths,” said Martti Hedman,
chief executive officer of Colorcon Inc. “With
the addition of new technologies, we look forward to providing increased value
for our pharmaceutical customers, strengthening our market leadership position,
and continuing to be their supplier of choice”.
The alliance portfolio will comprise: the
controlled release technologies including
·
Methocel CR Cellulose Ethers,
·
Ethocel polymers and Polyox resins as well as
the additional excipient technologies including
·
Affinisol polymers for solubility
enhancement,
·
Enteract polymers for enteric tablet
coatings, and
·
Duolite and Amberlite ion exchange resins for
controlled release and other applications.
Affinisol is
a new science-driven offering to enhance the solubility profile of poorly
soluble active pharmaceutical ingredients, one of the most pressing needs of
the pharmaceutical industry today. This innovative technology is ideal for
formulating BCS Class II and Class IV compounds via spray dry dispersion or hot
melt extrusion, the two leading processing technologies in the field.
In addition, Amberlite and Duolite are powdered ion exchange resins used as
formulation excipients. The technologies have a broad range of applications,
including taste-masking, tablet disintegration, modified release and the
formulation of poorly soluble or unstable drug compounds.
“The
expansion of the Alliance portfolio enables Dow to extend a more robust
pharmaceutical offering to a wider base of customers through this collaboration,”
said Marc van Gerwen, business director of Dow Pharma & Food Solutions. “Dow’s long standing relationship with
Colorcon is rooted in the belief that the Company’s innovation and
manufacturing excellence is complemented perfectly by Colorcon’s global reach
and deep technical expertise.”
The agreement also renews the Alliance
innovation partnership, in which Colorcon and Dow collaborate on the
development and commercialization of the next generation controlled release excipients.
The partnership’s efforts focus on areas such as productivity improvement and
manufacturing efficiency for the pharmaceutical industry.
Comments
Post a Comment